Histamine H2receptor antagonists |
| Neonates: 5 to 10 mg per kg per day, divided every 8 to 12 hours Infants: 10 to 20 mg per kg per day, divided every 6 to 12 hours ≤ 12 years: 20 to 40 mg per kg per day, divided every 6 hours > 12 years: 400 mg every 6 hours or 800 mg every 12 hours
| | Affects cytochrome P450, vitamin D metabolism, endocrine function Improves symptom scores, reflux index, and histologic and endoscopic findings in infants and children
| |
| 0 to 3 months: 0.5 mg per kg per day 3 to 12 months: 0.5 mg per kg twice daily 1 to 16 years: 0.5 mg per kg twice daily
| | | |
| 6 months to 11 years: 5 to 10 mg per kg per day, divided every 12 hours ≥ 12 years: 150 mg twice daily
| | | |
| Infant to 16 years: 5 to 10 mg per kg per day, divided every 12 hours; maximum dosage of 300 mg per day > 16 years: 150 mg twice per day
| | Most commonly used H2 receptor antagonist No evidence for symptomatic improvement in infants, but has shown symptomatic benefit in children Improves reflux index and histologic and endoscopic findings in infants and children
| |
Proton pump inhibitors |
| 1 to 11 years: 10 mg per day ≥ 12 years: 20 mg per day (alternative dosage for infants, children, and adolescents: 0.7 to 3.3 mg per kg per day)
| | Approved for up to 8 weeks of treatment Improves reflux index in infants; no evidence of improvement in symptom scores Improves symptom scores and histologic and endoscopic findings in children
| |
| ≤ 30 kg: 15 mg per day > 30 kg: 30 mg per day
| | Improves symptom scores, reflux index, and histologic and endoscopic findings in children No evidence of effectiveness in infants Approved for 12 weeks of use in children and 8 weeks of use in adolescents Well tolerated in children
| |
| | | | |
| < 15 kg: 5 mg per day ≥ 15 kg: 10 mg per day
| | Lacks evidence of effectiveness in infants and children Approved for up to 12 weeks of use in children 1 to 11 years of age Approved for up to 8 weeks of use in children 12 years and older, and in adolescents
| |
Prokinetics | | |
| | | | |
| | | Lacks evidence showing effectiveness in infants and children No specific dosing recommendations for GERD Associated with hypertrophic pyloric stenosis in infants younger than 6 weeks
| |
| | | Not recommended for routine treatment of GERD 34% of treated patients have adverse effects (drowsiness, restlessness, rare extrapyramidal symptoms); use is generally not recommended
| |
Buffering agents |
| | | FDA approved for infants (magnesium hydroxide only), children, and adolescents May produce milk alkali syndrome; caution in renal disease
| |
Surface protective agents |
| | | | |